Valuation
- Market cap
- 129,019,000
- Revenue TTM
- $4,710,000
- Net income TTM
- $-58,010,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,231.63%
- Debt to equity
- 2.15
Trading
- Volume
- 2,255,300
- Avg volume
- 1,207,428
- Day's range
- $0.63 – $0.68
- Shares out
- 203,244,000
- Stochastic %K
- 31%
- Beta
- 1.12
- Analysts
- Strong Sell
- Price target
- $4.00
Company profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal...
Show more
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 917 813 1828
- Website
- https://www.luciddx.com
- Address
- 360 Madison Avenue, 25th Floor, New York, United States
Latest news
No headlines yet.
